Dr. Michael Boehler Joins clock.bio as Chief Business Officer
Boehler Brings Global Commercial Leadership From BioNTech's mRNA Vaccine Rollout to Accelerate clock.bio's Rejuvenation Biology Platform and Advance Therapies That Extend Healthspan
clock.bio, a rejuvenation biology company dedicated to developing innovative therapies for reversing aging, has announced an exciting new appointment. Dr. Michael Boehler, a former executive at BioNTech, has been appointed as Chief Business Officer. His extensive experience in the life sciences sector is expected to significantly enhance the company’s business development and commercialization strategies.
Dr. Boehler's Expertise and Vision
Bringing over 20 years of diverse experience within the life sciences, Dr. Boehler has been a pivotal player in transforming BioNTech into a leader in the pharmaceutical industry. Known for his role in the company’s rapid scaling and successful product launches, he will leverage his strategic skills and expertise to drive clock.bio’s mission of extending human healthspan through pioneering rejuvenation therapies.
“Michael played a central role in one of the most significant product launches in pharmaceutical history,” said Markus Gstöttner, CEO of clock.bio. “With his proven ability to foster partnerships and his experience in global commercial scale-up, we are confident he is the right leader to help us translate our groundbreaking science into impactful therapies.”
Impact on clock.bio's Future
Dr. Boehler's extensive background includes senior positions at other leading companies such as Takeda, Kite Pharma, and Amgen, where he honed his expertise specifically in oncology. His experience will be crucial as clock.bio aims to establish strategic partnerships that will further enable the development and distribution of its rejuvenation biology platform.
“Rejuvenation biology offers an extraordinary opportunity to change the landscape of healthcare,” Dr. Boehler shared. “I’m excited to collaborate with such a forward-thinking team at clock.bio, where we can utilize our abilities to decode the rejuvenation genome and turn those insights into effective interventions.”
Advancing Healthspan Through Innovative Technology
clock.bio is on a mission to build strategic partnerships and commercial channels that resonate with their rejuvenation biology platform. Focusing initially on topical and nutraceutical solutions provides a clear market path while generating significant data that supports the future development of comprehensive systemic therapies.
Recent advancements have demonstrated the potential of using human induced pluripotent stem cells (iPSCs) to explore aging reversals and rejuvenation. The company’s proprietary platform utilizes three core technologies aimed at decoding the rejuvenation genome with unprecedented efficiency and accuracy:
- geneAge Atlas of Aging and Rejuvenation Genes – The first comprehensive genome-wide map identifying over 150 key genetic targets through CRISPR screening in human cells.
- imAge – An AI-driven system assessing biological age through single-cell images, enabling swift evaluation of rejuvenation interventions.
- clinAge Platform – A next-generation clinical engine facilitating rapid and adaptive human validation of rejuvenation therapies.
Transformative Potential in Aging Science
Together, these technologies form a unique discovery-to-validation engine that seamlessly connects stem cell research to real-world applications. By focusing on both medical and aging challenges, clock.bio seeks to turn scientific advances into real interventions aimed at improving human healthspan.
About clock.bio
clock.bio is at the forefront of rejuvenation biology, committed to developing therapies that can extend human healthspan. The pioneering work has unveiled that iPSCs can age artificially and rejuvenate spontaneously, leading to the identification of genetic pathways governing cellular aging. By collaborating with top-tier institutions and investors, including LocalGlobe and BlueYard Capital, the company is laying the groundwork to produce measurable interventions that support new paths in therapeutic development.
Frequently Asked Questions
What role will Dr. Michael Boehler have at clock.bio?
Dr. Boehler will serve as the Chief Business Officer, focusing on business development, partnerships, and commercialization strategies.
What is clock.bio's primary focus?
clock.bio's main focus is developing therapies that reverse aging and extend human healthspan through its rejuvenation biology platform.
How does clock.bio's technology work?
The technology involves decoding the rejuvenation genome utilizing advanced approaches like CRISPR screening and AI-driven analyses.
What expertise does Dr. Boehler bring?
With over two decades in the life sciences, Dr. Boehler has significant experience in commercial roles, especially noted for his work at BioNTech.
What are the goals of clock.bio moving forward?
clock.bio aims to establish partnerships that lead to the rapid development of therapies designed to enhance human health and longevity.
